Welcome to Abbott's first-quarter 2025 earnings conference ... Good morning, everyone and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil ...

The expanded facilities are expected to “go live” by the end of the year, Abbott Laboratories Chairman and CEO Robert Ford said during the company's first-quarter earnings call Wednesday.

EPS: US$0.76 (up from US$0.70 in 1Q 2024). We've discovered 1 warning sign about Abbott Laboratories. View them for free. Revenue was in line with analyst estimates. Earnings per share (EPS ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results tomorrow before the bell. Here’s what to look for. Abbott Laboratories met analysts ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks. As per BlackRock, 2025 started with a bumpy ride for the US stocks.

Abbott Laboratories plans to hire as many as 200 ... to boost manufacturing and jobs in the U.S. Abbott CEO and Chairman Robert Ford said during a call with investors Wednesday morning that ...

Abbott Laboratories recently announced promising results from its AVEIR Conduction System Pacing study, showcasing its innovative leadless pacemaker technology. Over the last quarter, the company ...

Robert Ford: Good morning, everyone, and thank you for joining us. As we progress through 2025, it is clear we are operating in an increasingly dynamic environment. Abbott Laboratories was built ...

Abbott Laboratories ABT reported better-than-expected ... business model delivered top-tier sales and EPS growth," said Robert Ford, chairman and CEO of Abbott. "It is this diversification and ...

Speaking of which, we noticed some great changes in Abbott Laboratories' (NYSE:ABT) returns on capital, so let's have a look. Trump has pledged to "unleash" American oil and gas and these 15 US ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that Jim Cramer discussed. In his latest appearance on CNBC’s Squawk on the ...